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Abstract 
Background 
There is a long-standing debate about the relationship between amphetamines and 
psychoses. While some have found psychoses induced by amphetamines to be 
indistinguishable from schizophrenia, others have found that psychoses induced by 
amphetamines, in contrast to schizophrenia, were characterized by visual hallucinations and 
lack of thought disorder. It has also been discusses whether there really are sharp 
boundaries between the two diagnoses, and whether there is a transition between them. 
Also, there are few studies which investigate the relationship between blood concentrations 
of amphetamines and clinical presentation, and whether methamphetamine could have a 
greater potential for generating psychoses than amphetamine. 
Objectives 
Our main objectives were to investigate whether there are clinically evident differences 
between psychosis induced by amphetamines and acute symptoms of schizophrenia, and if 
there is a transition from amphetamine-/methamphetamine induced psychosis to 
schizophrenia. We also wanted to study the relationship between blood concentrations of 
amphetamines and clinical presentation, and if methamphetamine was more potent in 
generating central nervous influence and psychosis than amphetamine. 
Methods 
The first source of data were  from two psychiatric wards at public hospitals, where blood 
and/or urine samples were collected as soon as possible after admission for 87 individual 
patients in 2003 and 285 in 2006/2007. Psychotic symptoms were assessed with the positive 
subscale of the Positive and Negative Symptom Scale (PANSS) for the patients admitted in 
2006/2007. The second source of data came from the Norwegian Institute of Public Health 
(NIPH) where all blood samples from apprehended drivers in Norway are analysed. Blood 
samples were obtained from 735 apprehended drivers from the same time periods and the 
same geographical area as the acutely admitted patients. On the basis of blood drug 
concentrations among patients admitted to psychiatric wards and among apprehended 
drivers, drug influence was estimated. In 2012, we did a follow-up by reviewing their hospital 
records of 35 patients who were admitted to one of the two hospitals and were positives for 
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amphetamines in 2006/2007. From these 12 individual patients received diagnoses 
specifically related to disorders due to psychoactive substance use (F10-F19 according to the 
ICD-10 classification of mental and behavioural disorders). 
Results 
We compared positive PANSS scores for 1) patients who received a diagnosis of 
schizophrenia and were negatives for amphetamines in blood and/or urine with 
PANSS scores (N=8), to 2) patients who were positive for amphetamines in blood 
and/or urine and either received a diagnosis of amphetamine-induced psychosis or 
psychoses induced by multiple drugs (N=31). We found no differences between 
the two groups (total PANSS 23.5 vs 22.8, p=0.783). With rising blood levels of 
amphetamines no differences in symptoms, as measured by PANNS, were 
observed (urine positives only total PANSS 18.0, low/moderate blood 
concentrations 20.6, high blood concentrations 20.9, p=0.782). Having 
amphetamines in the blood increased the likelihood of being judged clinically to be 
under the influence of drugs (OR 5, 95% CI 1-17) compared to having other 
substances in the blood. We found that individuals who had taken 
methamphetamine had a 3-4 times increased risk of being admitted to an acute 
psychiatric ward compared to those who had taken only amphetamine (adjusted 
OR= 4.423 (2.031 – 9.631)). The apprehended drivers were the comparison group 
here. When we did the follow-up in 2012, four patients who had not been 
diagnosed with schizophrenia before, now had got this diagnosis, all in the period 
2008–2010. 
Conclusions 
In acute phase, i.e. at the time of admission to acute psychiatric wards, it is not possible to 
distinguish patients with psychoses induced by amphetamines from patients with 
schizophrenia. An important clinical implication is that patients with dual diagnosis may be 
mis-diagnosed as only having a drug-induced psychosis and may not receive the correct 
treatment). Also, we found no relationship between symptoms and blood concentrations of 
amphetamines and no strong relationship between being positive for amphetamines and 
being judged as under the influence of drugs by the physician on call. On the basis of our 
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main findings, we propose a traditional stress-vulnerable model for understanding the 
relationship between psychosis induced by amphetamines and schizophrenia. 
4 
Sammendrag på norsk 
Bakgrunn 
Det har lenge hersket uenighet om forholdet mellom amfetaminer (amfetamin og 
metamfetamin) og psykoser. Mens noen har funnet at psykoser framkalt av amfetaminer var 
umulige å skille fra schizofreni, har andre funnet at amfetaminutløste psykoser, i motsetning 
til ved schizofreni, var kjennetegnet av synshallusinasjoner og mangel på tankeforstyrrelser. 
Det har også vært diskutert om det egentlig fins skarpe skillelinjer mellom de to diagnosene, 
og om den ene kan gå over til den andre. I tillegg er det få studier som har studert forholdet 
mellom amfetaminkonsentrasjoner i blod og det kliniske bildet, og om metamfetamin i 
større grad fører til psykotiske symptomer enn amfetamin. 
Forskningsspørsmål 
Vårt hovedmål var å studere om det er klinisk viktige forskjeller mellom psykoser utløst av 
amfetaminer akutte symptomer ved schizofreni, og om en overgang skjer mellom de to. Vi 
ønsker også å studere forholdet mellom amfetaminkonsentrasjoner i blod og klinisk bilde, og 
om metamfetamin i større grad enn amfetamin førte til psykotiske og sentralnervøse 
symptomer. 
Metoder 
Den første datakilden var fra to psykiatriske akuttavdelinger fra to norske sykehus, der blod- 
og urinprøver ble tatt så raskt som mulig etter innkomst. Det ble tatt prøver av 87 pasienter i 
2003 og fra 285 pasienter i 2006/2007. Psykotiske symptomer ble vurdert ved hjelp av 
positiv subskala fra Positive and Negative Symptom Scale (PANSS) for de pasientene som ble 
innlagt i 2006/2007. Den andre datakilden kom fra Nasjonalt folkehelseinstitutt, som 
analyserer blodprøver fra alle anholdte bilførere i Norge. Derfra kom blodprøver fra 735 
bilførere fra samme tidsperiode og fra samme geografiske område som blodprøvene fra 
sykehusene kom fra. På grunnlag av konsentrasjonene av ulike stoffer i blodprøvene hos 
begge gruppene, ble graden av ruspåvirkning anslått. I 2012 gjorde vi en oppfølgingsstudie 
der vi gikk gjennom innleggelsesjournalene til de 35 pasientene som var innlagt på ett av de 
to sykehusene og som var positive for amfetaminer i 2006/2007. Av disse hadde 12 fått en 
rusdiagnose (F10-F19 ifølge ICD-10 diagnosene av psykiske lidelser og atferdsforstyrrelser). 
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Resultater 
Vi sammenliknet PANSS-scorene fra 1) pasienter som fikk diagnosen schizofreni og hadde 
blod- og urinprøver som var negative for amfetaminer (N=8), med 2) pasienter som hadde 
blod- og urinprøver som var positive for amfetaminer og enten fikk diagnosen 
amfetaminutløst psykose eller psykose utløst av flere stoffer (N=31). Vi fant ingen forskjeller 
mellom de to gruppene (total PANSS 23.5 vs 22.8, p=0.783). Ved økende 
blodkonsentrasjoner for amfetaminer fant vi ingen forskjeller i symptomer målt ved PANSS 
(bare positive urinprøver total PANSS 18.0, lav/middels blodkonsentrasjon 20.6, høy 
blodkonsentrasjon 20.9, p=0.782). Å ha amfetaminer i blodet økte sannsynligheten for å bli 
klinisk vurdert som ruspåvirket (OR 5, 95% CI 1-17) sammenliknet med å ha andre stoffer i 
blodet. Vi fant også at de som hadde tatt matamfetamin hadde 3-4 ganger økt risiko for 
psykiatrisk innleggelse sammenliknet med dem som bare hadde tatt amfetamin (justert OR= 
4.423 (2.031 – 9.631). Bilførerne var her sammenligningsgruppen. Da vi gjorde 
oppfølgingsstudien i 2012, hadde fire pasienter som tidligere ikke hadde hatt diagnosen, fått 
diagnosen schizofreni i løpet av tidsrommet 2008-1010. 
Konklusjon 
I akuttfasen, det vil si ved innleggelse i psykiatriske akuttavdelinger, er det ikke mulig å skille 
pasienter med psykoser utløst av amfetaminer fra pasienter med schizofreni. En viktig klinisk 
implikasjon er at pasienter med dobbeltdiagnoser kan bli feildiagnostisert til å ha bare en 
rusutløst psykose og dermed ikke få riktig behandling. I tillegg fant vi ingen sammenheng 
mellom symptomer og amfetaminkonsentrasjoner i blod, og heller ingen sterk sammenheng 
mellom å være amfetaminpåvirket og å bli vurdert som ruspåvirket av vakthavende lege. På 
grunnlag av våre hovedfunn vil vi foreslå en tradisjonell stress-sårbarhetsmodell for å forstå 
sammenhengen mellom psykose utløst av amfetaminer og schizofreni. 
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Study background 
In 2004, I started working as a ward psychiatrist on the acute psychiatric ward at Lovisenberg 
Diakonale Hospital in Oslo. The ward had 27 beds and served approximately  
100 000 inhabitants. Crisis intervention and diagnostic evaluation were the ward’s main 
activities. Typical problems among admitted patients were suicide risk and acute psychoses. 
Many were also under the influence of different kinds of drugs, including stimulating drugs, 
mostly amphetamine. Among those who were admitted with psychotic symptoms, some 
were already diagnosed with schizophrenia, some had recognized drug use problems, and 
some had both. A dilemma emerged for the psychiatrists with regard to some of these 
patients. When a patient was admitted and had both psychotic symptoms and a recognized 
drug problem, could we assume that the psychotic symptoms were due to drug use alone or 
could some of these patients have schizophrenia as well? Also, some patients seemed to 
take longer with each successive admission to recover from their psychotic symptoms. Could 
some patients who originally presented with drug-induced psychoses be developing 
schizophrenia? 
Similar discussions were taking place at other psychiatric hospitals in Oslo. One hospital 
refused to accept patients with a drug history and channelled them to drug service units, 
which at the time were sparse. A major argument from those working at that hospital was 
that everyone who uses stimulating drugs like amphetamine would eventually develop 
psychotic symptoms. Was this really the case? 
The discussion had implications for treatment as well. If psychotic patients with a history of 
drug abuse were admitted to acute psychiatric wards, should they be discharged after a 
slight improvement of symptoms on the assumption that the rest of the symptoms would be 
gone in a few days? Or would some of these patients have persisting psychotic symptoms? 
Perhaps some had schizophrenia or developed schizophrenia during the course and were 
not receiving the correct treatment. There was also uncertainty about treatment. Should 
drug-induced psychoses in the initial phase be treated with antipsychotics (1;2), 
benzodiazepines (3) or a combination of the two? There is little knowledge from empirical 
evidence about which treatment to choose for amphetamine psychoses (4).  
We also had the impression that there was in increase in the number of amphetamine-
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induced psychoses. We knew that both amphetamine and methamphetamine were available 
on the drug market in Oslo at the time, but noticed that the patients did not seem able to 
distinguish between the two and called both of them “amphetamine”. Did 
methamphetamine slowly replace amphetamine on the market, and was the perceived 
increase of drug-induced psychoses related to this shift?  
These were questions to which neither I nor my colleagues knew the answers. During 2003 
and 2006/2007, researcher Jørgen G. Bramness at the Norwegian Institute of Public Health 
and, then PhD student, Jon Mordal initiated a study on the ward where I worked at 
Lovisenberg Diakonale Hospital. The aim was to study dual-diagnosis patients on acute 
psychiatric wards. As a ward psychiatrist, I became quite involved in the collection of data 
and had the main responsibility for asking patients to participate in the study. I started 
seeing the possibility of combining my experience of dual diagnoses as a clinician with my 
interest in research. Hence, I started my PhD project in 2009 with the aim of studying the 
amphetamine-positive patients from the study. 
8 
 Papers 
I. A comparison of symptoms and drug use between patients with methamphetamine 
associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric 
wards (Sigrid Medhus, Jon Mordal, Bjørn Holm, Jørg Mørland, Jørgen G. Bramness) 
II. Influence of drugs of abuse and alcohol upon patients admitted to acute psychiatric 
wards: Physician’s assessment compared to blood drug concentrations (Jon Mordal, Sigrid 
Medhus, Bjørn Holm, Jørg Mørland, Jørgen G. Bramness) 
III. Association between methamphetamine versus amphetamine and acute psychiatric 
symptoms (Sigrid Medhus, Bjørn Holm, Jørg Mørland, Jørgen G. Bramness) 
IV. Methamphetamine positive patients admitted to acute psychiatric wards – a follow-up 
five years later (Sigrid Medhus, Michael Gossop, Bjørn Holm, Jørg Mørland, Jørgen G. 
Bramness)
9 
 
 
1. Introduction 
1.1 Amphetamines and psychoses 
The use of amphetamine and methamphetamine, here called amphetamines, is widespread 
(5), particularly in Southeast Asia (6) and North America (7-9), but also in Europe (10), 
Australia (11;12) and South Africa (13). In Europe, amphetamines are most common in 
Central and Northern Europe (14). In most of this area, amphetamine is found much more 
frequently than methamphetamine. The exception is the Nordic and the Baltic countries, 
and especially Norway, where methamphetamine has obtained an important position 
(10;15).  
Amphetamines use is not common in the general population. The lifetime prevalence of 
amphetamines in Europe ranges from 0.1% to 3.6% for most European countries. Nearly 
3.5% of all Europeans have tries amphetamines at least once, but only 0.7% on average 
(range 0 – 1.3%) have used it last year (16). In Norway, the lifetime prevalence for 
amphetamines is 3 - 4% (16-18). However, use of amphetamines is far more frequent among 
psychiatric patients (19-21). There is a link between the use of amphetamines and psychoses 
(22-25), and individuals patients who are not receiving psychiatric treatment and have no 
known primary psychotic disorder can have psychotic symptoms (26;27). When patients who 
use amphetamines are admitted to acute psychiatric wards, drug-induced psychosis can be 
difficult to distinguish from other psychotic disorders. Also, these patients often require 
considerable resources because of agitation and aggression (28-31), and there is a debate 
about whether they should be treated by psychiatric or drug-misuse services (32), or by 
integrated teams for dual diagnosis (33). Poly drug use is common; both recreational 
methamphetamine users and acutely admitted psychiatric patients commonly use tobacco, 
alcohol, ecstasy, tobacco and cannabis and to a lesser extent opioids and benzodiazepines 
(19;27;34-38).  
There is a long-standing debate about the relationship between amphetamine and 
methamphetamine on the one hand and schizophrenia and psychosis on the other. Some 
found that the symptoms of amphetamine-induced psychosis were so similar to the 
symptoms found in schizophrenia (39;40), that they proposed the first as a model for the 
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latter (41-43). Others found that amphetamine-induced psychosis, in contrast to 
schizophrenia, was characterized by visual hallucinations and lack of thought disorder (44-
46). Interestingly enough, in two early observational studies the authors noted two different 
courses among patients with amphetamine-induced psychoses: one group had psychotic 
episodes that cleared within 10 days, the other had a prolonged course which lasted for 
months and was very similar to schizophrenia (44;46). Another author noted that a few 
amphetamine-psychotic patients continued to experience psychotic symptoms long after 
amphetamine withdrawal (43). 
In early experimental studies, amphetamine was given to amphetamine users either orally 
(40;42;47;48) or as injections (45;49). These studies showed that amphetamine can cause 
psychotic symptoms such as suspiciousness, delusions of persecution and auditory and visual 
hallucinations. These early studies also noted that the same dose may induce psychotic 
symptoms in some individuals but not in others (41;45;47;48), but more individuals develop 
psychotic symptoms on high doses of amphetamine (41) than on low (47). Some found that 
all (45;47;50) or nearly all (49) became psychotic after administration of amphetamine, but 
several of these were recruited from psychiatric wards and had experienced psychoses 
earlier. Others found that not all individuals developed psychotic symptoms, even at high 
doses of amphetamine (42;45;48;51). One author notes that “Those who denied formal 
psychotic experiences with past use tended not to experience them in the course of the 
experiment” (42). 
Later observational studies also have inconsistent conclusions with regard to psychoses 
induced by amphetamine or methamphetamine versus schizophrenia. Some have found that 
visual hallucinations are common among methamphetamine users (52-55). Others have 
found it difficult to distinguish between methamphetamine-induced psychoses and 
schizophrenia (56-58). Yet others have found visual hallucinations among those who have 
used high doses of methamphetamine and not among those who have used low doses (59).  
The similarities are so pronounced there has been discussion about whether there really are 
sharp boundaries between the two diagnoses. The western view has been that drugs cannot 
produce prolonged psychotic syndromes, i.e. according to the ICD-10 classification, the 
psychotic symptoms must not exceed six months if a condition is to be called psychotic 
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disorder due to use of drugs (60). The Japanese view, on the other hand, has been that 
heavy use of amphetamine can precipitate a chronic psychosis indistinguishable from 
schizophrenia in individuals who would not otherwise have developed a psychotic disease. 
Japanese researchers describe different clinical courses of methamphetamine psychoses in 
different patients: some clear up after a short time, some have a protracted course of 
psychosis, and some develop chronic psychoses (58;61;62). Also, some experience psychotic 
recurrence even after long-term abstinence, up to five years (31;63-65). During flashbacks, 
they had psychotic symptoms such as paranoid delusions and auditory and visual 
hallucinations (66). 
In the western psychiatric tradition, psychotic symptoms after several years of abstinence 
from amphetamines would be regarded as schizophrenia (60;67;68). Some of the later 
observational studies found that those with methamphetamine-induced psychosis did not 
have negative symptoms in the acute phase whereas those diagnosed with schizophrenia did 
(69;70). Others found that methamphetamine-induced psychosis in the acute phase 
resembled schizophrenia with regard to negative symptoms like affective flattening and 
psychomotor retardation (3;56;57;71), but as one author notes, these negative symptoms 
may be due to undetected primary psychoses (56). 
The stability of the diagnoses drug-induced psychosis versus schizophrenia has also been 
discussed. There is considerable overlap between patients who receive a diagnosis of 
substance-induced psychosis, and those who later receive a diagnosis of schizophrenia 
(72;73). One study shows that among inpatients who receive a diagnosis of substance-
induced psychosis, 25% had received a diagnosis of primary psychosis one year later (74). 
Another study showed that among patients who were hospitalized because of psychosis and 
concomitant methamphetamine use, 38.8% had received a diagnosis of schizophrenia due to 
persistent psychosis at follow-up (75). 
 
1.2 Amphetamine and methamphetamine in Norway 
In most of Europe, as opposed to the rest of the world, amphetamine use is more prevalent 
than methamphetamine (14). However, in the Baltic and Nordic countries, 
methamphetamine is increasingly dominant (14) as in North America, Mexico and South-
12 
East Asia (5). Previously, most of the supply to Norway was amphetamine produced in the 
Netherlands or Poland. More recently, smuggling via the “Baltic Route”, i.e. from the Baltic 
states, mainly Lithuania and to some extent Estonia, has taken over. Here, the traffickers 
seem to have switched to producing mostly methamphetamine as opposed to amphetamine 
(14). 
Data from several sources show that methamphetamine makes up an increasing proportion 
of the total use of amphetamine in Norway. While the total number of seizures of 
amphetamines made by the National Criminal Investigation Service has remained relatively 
constant, methamphetamine increased from 2% of all amphetamine seizures in 2000 to 64% 
in 2009 (76). Data from the National Institute of Public Health (NIPH) in Norway which 
analyses blood samples of apprehended drivers show the same tendency. In 2000, among 
Norwegian drivers suspected of driving under the influence and testing positive for 
amphetamines, methamphetamine was found in only 3% of the samples. In 2009, this had 
risen to 35% (77). In a study of injured patients admitted to a Norwegian emergency 
department in 2007/2008, methamphetamine was detected in about 80% of patient 
samples positive for amphetamines (78). 
The Division of forensic medicine and drug abuse research at the Norwegian Institute of 
Public Health has also analysed urine samples from inmates in Norwegian prisons and from 
post-mortems. All analyses have been carried out using chromatographic-mass 
spectrometric methods and show the same tendency of increasing use of 
methamphetamine and decreasing use of amphetamine, while the total amount of the two 
remains relatively constant (79). 
In Europe, methamphetamine is not in crystalline form (ice), but rather a white powder 
indistinguishable from amphetamine (14) and it is eaten, snorted or injected (79;80). One 
study suggests that among the marginalized users of amphetamines, injection is very 
common, as opposed to integrated users who do not inject (38). The prices of amphetamine 
and methamphetamine are very similar in Europe (10;81). It has been confirmed in studies 
amongst users of amphetamines that they, most often, do not know what they are buying 
and using (80). It, therefore, seems unlikely that any group would be selected into using 
amphetamine or methamphetamine specifically. 
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1.3 Amphetamine and methamphetamine pharmacology 
Both amphetamine and methamphetamine stimulate the central nervous system and can 
give wanted effects like increased alertness, euphoria with wakefulness and feelings of 
energy and increased sexual drive (82). These reactions are rewarding and connected to 
different types of stimuli, meaning development of incentive salience, which motivates 
further intake (83). Not so sought-after effects include anxiety, aggression, prolonged 
sleeplessness as well as psychotic symptoms as described above. Amphetamine and 
methamphetamine can also give side effects like hypertension, tachycardia, dysrhythmia, 
dyspnea and tachypnea as well as serious condition like seizures, stroke and myocardial 
infarction (84;85). Both act by releasing synaptic catecholamines, i.e. dopamine, adrenaline 
and noradrenaline, and inhibiting their presynaptic uptake (86-89). 
Methamphetamine has one additional methyl group compared to amphetamine (90). 
Methamphetamine is, therefore, presumed to be more lipid soluble (91) and more difficult 
to metabolize than amphetamine (92). Theoretically, this should make methamphetamine 
act more potently and for longer (89). Methamphetamine is also perceived as a more potent 
drug of abuse in clinical practice (80). However, both amphetamine and methamphetamine 
are mostly renally excreted (93) and only metabolized to a lesser extent and, when used 
therapeutically, amphetamine and methamphetamine are dosed similarly (94). Still, it is 
reasonable to ask whether methamphetamine could have a greater potential for generating 
psychoses than amphetamine. It has been difficult to find empirical support for this notion. 
Small studies in humans showed that subjects perceived the two drugs as very similar (95-
97). Several preclinical animal studies have not found methamphetamine to be more potent 
(98-100) or have found it to be only slightly more potent than amphetamine (101). Other 
studies suggest that the difference between the two drugs is more qualitative than 
quantitative, with methamphetamine affecting different regions of the brain than 
amphetamine (102-104). We have not found any empirical studies supporting the notion 
that methamphetamine is more potent than amphetamine in generating psychoses. 
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2. Objectives 
x What are the clinically evident differences between amphetamine-/methamphetamine-
induced psychosis and acute symptoms of schizophrenia? 
x What is the relationship between blood concentrations of amphetamines and clinical 
presentation? 
x Is methamphetamine more potent in generating central nervous influence and psychosis 
than amphetamine?  
x Is there a transition from amphetamine-/methamphetamine induced psychosis to 
schizophrenia? 
 
Specific research aims: 
1. How many patients acutely admitted in a psychiatric ward were positives for 
amphetamine/methamphetamine? (paper I and III) 
2. Which other psychoactive drugs did the amphetamine positives have in their 
blood/urine? (paper I and III) 
3. Which socio-demographic characteristics do the amphetamine-postive patients have? 
(paper I) 
4. What are the symptoms of psychosis induced by amphetamines compared to 
schizophrenia in the acute phase? (paper I and IV) 
5. Is there a relationship between blood concentrations of amphetamines and psychotic 
symptoms? (paper I) 
6. What is the relationship between having positive blood samples for amphetamines and 
physician’s assessment of drug influence? (paper II) 
7. Is methamphetamine more prevalent than amphetamine among acutely admitted 
patients compared to apprehended drivers? (paper III) 
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8. Are there any differences in concentrations between amphetamine and 
metamphetamine among psychiatric patients compared to DUI cases? (paper III) 
9. How many of those diagnosed with amphetamine-/methamphetamine-induced 
psychosis later receive a diagnosis schizophrenia? (paper IV) 
10. What characterises those who experience this transition? (paper IV) 
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3. Material 
3.1 Setting  
Data for this study were taken from two sources. The first source of data were from 
two psychiatric wards at public hospitals, both with crisis intervention and diagnostic 
evaluation as their main activities, namely Lovisenberg Diakonale Hospital, Oslo, 
Norway and Sørlandet Hospital, Arendal, Norway. A pilot was conducted in 2003 and 
the main study in 2006/2007. In 2012, we did a follow-up of all patients at Lovisenberg 
Diakonale Hospital who were positives for amphetamine or methamphetamine or 
both in the main study.  
The second source of data came from the Norwegian Institute of Public Health (NIPH) 
where all blood samples from apprehended drivers in Norway are analysed. All DUI 
cases positive for amphetamine and/or methamphetamine during 2003, 2006 and 
2007 were included, i.e. from the same time intervals as the data for the pilot and the 
main study were collected from the psychiatric wards. 
 
3.2 Study samples 
The study sample is summarized in table 1. Paper I consists of data from the main 
study on the two psychiatric wards at Lovisenberg Diakonale Hospital and Arendal 
Hospital. Exclusion criteria were dementia or mental retardation. From a total of 462 
admissions, 13 (2.8%) did not give blood or urine samples, 84 (18.2%) declined, 16 
(3.5%) were excluded because of dementia and 6 (1.2%) were not asked to participate, 
leaving 343 admissions (74.2%). Because 37 patients were admitted more than once 
during the project period, this comprised 285 individual patients who were included in 
the study.  
Paper II also consists of data from the main study, but here we included only those 
who had volunteered blood samples and were assessed by a physician within six hours 
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of admission. In this paper, 271 admissions comprising 214 individual patients were 
included. 
In paper III, patients from the pilot study of 116 admissions were included in addition 
to the main study. Again, exclusion criteria were dementia or mental retardation, and 
we only included those who had given blood samples, giving us a total of 100 
admissions and 87 individual patients from the pilot study. In total, 578 admissions, 
from whom 443 (76.6%) admissions comprising 372 individuals consented to 
participation in the study and volunteered blood samples within 48 hours. In this 
article, we also included DUI cases from the Norwegian Institute of Public Health 
(NIPH). The data were grouped according to county, enabling us to select data from 
the same geographical area and the same time periods as the patients, a total of 988 
cases comprising 735 individuals. 
For paper IV, we did a follow-up in 2012 of the 36 individuals, all admitted to 
Lovisenberg Diakonale Hospital in 2006/2007, who were positive for amphetamine 
and/or methamphetamine in blood and/or urine in the original study. One withdrew 
her consent, leaving us with 35 individual patients. 
 
Table 1 Number of admissions included in the study and in the different papers (N). 
Setting 
Total number of 
admissions/DUI-
cases 
Admissions/DUI-
cases included in 
the study 
Individual 
patients/DUI-
cases 
included in 
the study 
Paper I 
Individuals 
 
Paper II 
Admissions 
 
Paper III 
Individuals 
Paper IV 
Individuals 
Patients        
   Pilot 116 100 87   87  
   
Lovisenberg 
(Oslo) 
351 300 247 247 236 238 35 
   Arendal 111 43 38 38 35 38  
DUI-cases        
   Oslo 518 517 378   378  
   Arendal 471 471 357   357  
 
 
In articles I, III and IV, we studied individual patients, while in article II we studied each 
admission per se. Even if it would be more statistically correct to do all analyses with 
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regard to individuals and avoid double counting of individuals, this may have the 
disadvantage of making type II errors, and we have tried to balance these 
considerations in the papers. 
 
3.3 Inclusion and exclusion criteria 
For patients from the main study (papers I-III), the patients provided written informed 
consent. They were asked again if they were readmitted during the project period. The 
patients in the pilot did not give informed consent (paper III), see ethical 
considerations. Exclusion criteria were dementia and mental retardation, as diagnosed 
by the ward psychiatrist. The patients included in the follow-up, were sent a letter 
with information about the study (paper IV). Data from the DUI cases belonged to the 
criminal ward and were handled anonymously, which left informed consent 
unnecessary and enabled us to include all cases (paper III). 
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4. Methods 
4.1 measurements 
4.1.1 Laboratory analyses 
All blood and urine samples were analysed at the Division of Forensic Toxicology and 
Drug Abuse, Norwegian Institute of Public Health. This laboratory had been accredited 
since 1996 according to ISO 17025, which is the ISO standard for testing and 
calibrating laboratories by the Norwegian body for accreditation of laboratories (Norsk 
Akkreditering, Kjeller, Norway). Samples from the psychiatric wards and from the DUI 
cases were analysed in the same laboratory using exactly the same procedures. 
For all patients admitted to psychiatric wards, the blood and urine samples were 
collected as soon as possible after admission. For the patients admitted in 2003, the 
blood samples were taken after 15 minutes (median; range 2 minutes to 24 hours), 
and for the patients admitted in 2006/2007 30 minutes, (median, range 0 minutes to 
48 hours). Samples of whole blood for drug analyses were collected by laboratory staff 
simultaneously as blood samples for routine laboratory analyses were obtained. For 
drivers suspected of driving under the influence of alcohol and/or other drugs (DUI 
cases), blood samples were collected within a few hours after apprehension.  
All urine samples were screened for parent drugs and/or metabolites using enzyme 
multiplied immunoassay technique (EMIT) for benzodiazepines, barbiturates, 
dextropropoxyphene, opiates, methadone, cocaine, amphetamines (amphetamine, 
methamphetamine, khat and ecstasy), Lycergic Acid Diethylamide (LSD) and '9-
tetrahydrocannabinol (THC; active ingredient in cannabis), and using a gas 
chromatographic method for gamma hydroxy butyrate (GHB). Blood samples were 
screened using EMIT immunological test for morphine, codeine, amphetamines, 
cocaine and THC (105), and using liquid chromatography-mass spectrometry for 
benzodiazepines, meprobamate, carbamazepine and methadone (106) and using an 
enzymatic dehydrogenase method for alcohol (107). All positive screening results in 
urine and blood were confirmed and quantified using gas or liquid chromatography-
20 
mass spectrometry (108-112) (table 2).
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Table 2 Substances included in the study with analytic methods and cut-off values (ng/ml) for 
screening and confirmation in blood and urinea 
 Blood b Urine b 
Screening Confirmation Screening Confirmation 
Substance  Metho
d  
Cut-
off Method  
Cut-
off 
Metho
d  
Cut-
off  
Metho
d 
Cut-
off 
Benzodiazepines   -  -  -  - EMIT 200  - - 
   Diazepam  LC-MS  57 LC-MS  57 -  -  LC-MS  150 
   Oxazepam  LC-MS  287 LC-MS  287 -  -  LC-MS  144 
   Flunitrazepam  LC-MS  2 LC-MS  2 -  -  LC-MS  28 
   Clonazepam  LC-MS  9 LC-MS  9 -  -  LC-MS  32 
   Nitrazepam  LC-MS  14 LC-MS  14 -  -  LC-MS  25 
   Alprazolam  LC-MS 9 LC-MS  9 -  -  LC-MS  31 
Zopiclone  LC-MS  19 LC-MS  19 -  -  -  - 
Opiates  EMIT  85 -  -  EMIT  300 -  - 
   Morphine  -  -  GC-MS  15 -  -  LC-MS  29 
   Codeine  -  -  GC-MS  32 -  -  LC-MS  60 
Methadone  LC-MS  62 LC-MS  62 EMIT  300 LC-MS  62 
Dextropropoxyfen  LC-MS 68 LC-MS  68 EMIT  300 LC-MS  200 
Buprenorphine  -  -  -  -  EMIT  5 LC-MS  4 
Barbiturates LC-MS  4640 LC-MS  4640 EMIT  200 -  - 
Alcohold  ADH  0.002  
HS-GC-
FID  0.004  ADH  0.01  
HS-GC-
FID 0.01 
Amphetamines  EMIT  54 -  -  EMIT  300 -  - 
   Amphetamine  -  -  GC-MS  41 -  -  LC-MS  135 
   
Methamphetamine  -  - GC-MS 45 -  -  LC-MS  150 
   Ecstasy  -  -  GC-MS  58 -  -  LC-MS  77 
Cannabis  EMIT  9 GC-MS  1 EMIT  20 LC-MS  10 
Cocaine  EMIT  91 GC-MS  60 EMIT  300 LC-MS  60 
 
LC-MS indicates liquid chromatography-mass spectrometry; GC-MS, gas chromatography-mass 
spectrometry; 
EMIT, enzyme multiplied immunoassay technique; ADH, alcohol dehydrogenase method for alcohol; 
HS-GCFID, 
Headspace gas chromatographic flame ionisations detection. 
a Due to conversion from molar units, some of the numbers in the table may seem odd. Blood 
concentrations are given and plasma/blood concentration ratios for some drugs are markedly above 
1. Cut-off values are given for analyses performed in 2006-7.  
b Analyses in blood and urine also included lorazepam, ethylmorphine, isopropanol, methanol and 6-
monoacetylmorphine (6-MAM, a metabolite of heroine), and, in blood; carbamazepine, 
meprobamate, carisoprodol, phenazepam, midazolam, zolpidem, and, in urine; pholcodin, 
phencyclidine, lysergic acid, diethylamide (LSD) and 2-ethylidene-1.5-dimethyl-3.3-
diphenylpyrrolidine (EDDP, a metabolite of methadone). 
Urine gamma hydroxybutyrate (GHB) was analysed only on special request and urine creatinine and 
pH were analysed for all samples. 
c Phenobarbital. 
d Values given in %. 
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4.1.2 On-site urine testing 
The device already in routine use at Lovisenberg Diakonale Hospital was chosen for 
urine samples, “Clearview 6 Panel Drug Screen card” (Inverness Medical International, 
Bedford, UK). Urine samples were obtained by the staff who routinely documented in 
case notes. The patients were not observed when sampling. 
 
4.1.3 Physician assessment 
On admission, all patients were examined and interviewed by the physician on call. As 
a part of this research project, all physicians on call were also asked to fill in forms 
where the following was registered: 
1. Psychotic symptoms. 
The instrument we used to register psychotic symptoms was the positive subscale of 
the Positive and Negative Syndrome Scale (PANSS) (113), which is a rating instrument 
which assesses seven different symptoms of schizophrenia. The sub-scale we used, 
that rates positive symptoms, includes the items ‘delusions’, ‘conceptual 
disorganisation’, ‘hallucinatory behaviour’, ‘excitement’, ‘grandiosity’, ‘suspiciousness’ 
and ‘hostility’. All items can be rated from 1-7 with 7 as the maximum score, which 
means all patients could receive between 7 and 49 points. To not make the data 
collection to extensive, we did not register negative or cognitive symptoms. 
Information on background, admission and stay were obtained by collecting data from 
the records after discharge.  
2. Assessment of drug influence. 
On the basis of all the data available at assessment, the physicians on call completed a 
study form and answered the following question derived from the Clinical Test for 
Impairment: “In your opinion, is the patient under drug influence at admission: Not at 
all, mildly, moderately, markedly or uncertain?” (114) 
 
4.1.3 Review of medical records and clinical diagnoses 
Data were also collected from the medical records. At Lovisenberg Diakonale Hospital 
this was done by Jon Mordal, a then PhD-student, and at Arendal Sykehus by a 
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research assistant. Data were collected with regard to gender, age, educational level, 
type of accommodation, employment status, number of previous psychiatric 
admissions, duration of stay and use of coercion (seclusion, medication without 
consent and use of mechanical restraints). Information about medication given after 
admission was also registered. This made us able to exclude patients who had positive 
laboratory findings with regard to benzodiazepines and opiates because of drugs given 
in the ward after admission. Global assessment of functioning and symptoms (GAF, 
split version) (115;116) and ICD-10 diagnoses at discharge (60) were also registered. 
The diagnoses were routinely stated at discharge or either given by or confirmed by a 
ward psychiatrist. As a part of the project, 63.2% of the patients at Lovisenberg 
Diakonale Hospital were interviewed using the Norwegian 16-item version of the Mini-
International Neuropsychiatric Interview (MINI) (117) and the 7-item Iowa Personality 
Disorder Screen (118). These results were registered in the medical records and taken 
into account when the diagnoses at discharge were given. At Arendal Sykehus, these 
interviews were not done. 
We later grouped the following diagnoses together and called them “psychoses”: 
mental and behavioural disorders due to psychoactive substance use, psychotic 
disorder (F1x5), all diagnoses in the chapter schizophrenia, schizotypal and delusional 
disorders (F20-F29), and the following from the chapter on mood (affective) disorders: 
mania with psychotic symptoms (F30.2), bipolar affective disorder, current episode 
manic with psychotic symptoms (F31.2), bipolar affective disorder, current episode 
severe depression with psychotic symptoms (F31.5) and severe depressive episode with 
psychotic symptoms (F32.3). 
 
4.1.4 Comparisons of drug levels 
On the basis of earlier epidemiological and experimental studies, the different blood drug 
concentrations were assessed and given a certain level (114;119-123). Points were given for 
each interval, enabling us to compare drug levels across different drugs and to add the 
effects of these drugs (table 3).  
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4.2 Statistical analyses 
Analyses were performed using SPSS versions 16.0, 19.0 and 20.0. Count data were 
presented as numbers (%). Continuous data with approximate normal distributions 
were presented as means (SD) and those which did not as medians (range) (124). 
 
 
Table 4. Statistical packages and statistical analyses used in papers I, II, III and IV. 
 Paper number 
I II III IV 
Statistical 
package 
SPSS 16.0  x   
SPSS 19.0 x  x x 
SPSS 20.0   x x 
Statistical 
analyses 
Chi-square 
test x x x x 
Fisher’s Exact 
probability 
Test 
x    
Student’s t-
test x x x x 
ANOVA x    
Mann 
Whitney U-
test 
 x   
Pearson’s r  x   
Binary 
logistic 
regression 
 x x  
 
 
The Statistical Package for the Social Sciences (SPSS) versions 16, 19 and 20 were 
used to analyse the data. Differences between groups were analysed using the F2-
test or Fisher’s Exact Probability Test for categorical variables and Student’s t-test 
or ANOVA for continuous variables. Binary logistic regression was used to explore 
the interrelationship between the probability of being admitted to a psychiatric 
ward, the level of different sedating drugs and amphetamine concentrations. In a 
second step, a binary logistic regression analysis was performed with the group 
26 
(psychiatric patients vs. DUI case) as outcome and as drug concentrations of 
amphetamines or sedative drug points as confounders. In this analysis, all subjects 
where a drug was not detected were treated as having a drug level of zero for this 
drug (table 4). 
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5. Ethical considerations 
Paper I and II: The main study at Lovisenberg Diakonale Hospital and Arendal Hospital 
in 2006/2007 was conducted in accordance with the Declaration of Helsinki (125) and 
approved by the Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate. Blood samples were collected on admission, and during the first 
few days of admission, there was a complete discussion with potential participants, 
including if they consented to the blood samples’ being analysed for drugs. After the 
discussion, written informed consent was obtained.  
Paper III: Data from the acute psychiatric wards in 2006/2007 as described above. The 
data from the patients admitted to acute psychiatric ward in 2003 were collected 
anonymously and with no link to individual data like age, gender or diagnoses. Hence, 
according to the Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate no informed consent was needed. With regard to data from the 
DUI cases, they belonged to the criminal ward and were handled anonymously, which 
left informed consent unnecessary and enabled us to include all cases. 
Paper IV: All patients included in this paper were informed in writing about the 
follow-up, but no new consent was obtained. The follow-up was also approved by the 
Regional Committee for Medical Research.  
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6. Methodological considerations 
6.1 Study design 
Both the pilot at Lovisenberg Diakonale Hospital in 2003 and the main study at 
Lovisenberg Diakonale Hospital and Arendal Hospital in 2006/2007 were cross-
sectional studies. We used the main study from 2006/2007 to describe characteristics 
of and to compare symptoms and blood and urine values between different groups of 
patients acutely admitted to psychiatric wards. This study design does not enable us 
to say anything about cause-effect relationships because we do not have a time 
course to determine which factor came first, i.e. in this study, did the psychotic 
symptoms come before or after the exposure to amphetamines? 
A cross-sectional study is appropriate for studying prevalence. At Lovisenberg 
Diakonale Hospital and the Norwegian Institute of Public Health, we had data from 
two different time periods, 2003 and 2006/2007, which allowed us to compare how 
the prevalence of amphetamines changed over time among patients acutely admitted 
to psychiatric wards and among DUI cases. However, we did not have enough power 
to find significant differences. 
The five-year follow-up at Lovisenberg Diakonale Hospital was a prospective case 
series study. In a cohort study, information is collected about a group of individuals 
before a certain outcome, i.e. death or a certain disease. In our study, we collected 
data about 12 acutely admitted psychiatric patients who were positives for 
amphetamines in blood/urine and got a diagnosis of either drug-induced psychoses or 
amphetamine-induced psychosis. We then went through their records five years later 
to see how many had got a diagnosis of schizophrenia during the follow-up time. 
Hence, this part of the study can be regarded as a very small cohort-study where the 
patients who were acutely admitted were their own controls. 
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6.2 Internal validity 
6.2.1 Selection bias 
In the main study from 2006/2007, we wanted to study use of drugs among patients 
who were admitted to acute psychiatric wards. At Lovisenberg, 300 from a total of 
351 admissions were included (85%) and from Arendal 43 from 111 (39%). Taken 
together, 74% of acutely admitted patients were included. When we compared those 
who were included to those who were not, we found no differences with regard to 
gender, age or substance-related diagnoses at discharge (p>0.2 for all). Those who did 
not consent to participation, however, more often received a diagnosis of 
schizophrenia at discharge (41% vs 25%, p=0.037) and were more often involuntarily 
admitted (81% vs. 57%, p=0.003). From the 285 patients who were included in the 
study, 38 received a diagnosis of schizophrenia, and only four of these were positives 
for amphetamines. It is most likely, therefore, that as more patients with 
schizophrenia declined, more negatives for amphetamines declined. It is also likely 
that those who declined had more pronounced symptoms like suspiciousness and 
hostility than those who consented. This may imply that the PANSS scores among 
amphetamine negatives with diagnosis of schizophrenia would have been higher if all 
of them had consented to participate in the study. 
A comparison was also made between the included admissions from Lovisenberg in 
2006/2007 and data from computerized records of all admissions at the acute 
psychiatric ward at Lovisenberg in 2006 (N=1133). We found no differences with 
regard to age, gender, involuntary admissions, length of stay or diagnoses at 
discharge (p<0.2 for all). We found no significant differences between the patients 
from Arendal compared to those from Lovisenberg with regard to clinical or 
laboratory findings.  
In papers I, III and IV, we studied individual patients, while we studied the total 
number of admissions in paper II. When we compared analyses performed with 
regard to individuals compared to admissions, we got very similar results with no 
statistical or clinical significance. Because of over-powering when comparing 
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psychiatric admissions to DUI cases in paper III, only results with p < 0.01 have been 
reported. 
Since data from the DUI cases belonged to the criminal ward and were handled 
anonymously, informed consent was unnecessary and enabled us to include all cases. 
Therefore, there is no selection bias in the DUI cases.  
6.2.2 Information bias 
Information bias occurs when the individuals studied give wrong information or 
information is wrongly registered during the study for other reasons (126).  
Laboratory analyses 
The use of a two-step process with both screening and confirmation analyses which 
were used in this study, give high reliability and validity. Also, since the laboratory we 
used is a forensic laboratory, the cut-offs for all tests are set high to avoid false 
positives. Still, false negative results are still possible because some substances might 
have had concentrations below screening cut-off levels. Another possible source of 
false negatives is urine tampering (127), but the fact that creatinine and pH were 
within recommended ranges for all samples, indicates that tampering was not 
common. False negatives may imply that some of the 
amphetamine/methamphetamine negatives diagnosed with schizophrenia, who were 
used as a comparison group to amphetamine/methamphetamine positives with drug-
induced psychoses, should have been excluded from the comparison. Since the PANSS 
score between negatives with schizophrenia varied from 7 to 35 points, it is likely that 
those with higher scores were influenced by amphetamines and that the actual PANSS 
mean score should have been lower in the schizophrenia group. 
In this study, we used blood and urine concentrations of different drugs as an 
indicator of recent drug use. Earlier a good correlation has been demonstrated 
between methamphetamine as measured in urine and patient self-report of 
methamphetamine use (128). However, there are still methodological problems. 
Some substances have short half-lives and may not have been detected because 
the intake had occurred too early to be detected in the laboratory tests or 
because of test delay up to 24 hours. The opposite may also have occurred, i.e. 
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substances with long half-lives could be detected even if the patient’s symptoms 
were not influenced by the drug at admission, and the intake was not regarded by 
the physician as “recent”. Some of the patients may have been hospitalized during 
a withdrawal phase for methamphetamine rather than in an intoxication phase 
(129-131).  
Our method of estimating drug influence by grouping different concentrations for 
the different drugs and giving points for each interval, also poses methodological 
problems. Even if there is an established relationship on the basis of earlier 
epidemiological and experimental studies, the different blood drug concentrations 
were assessed and given a certain level (114;119-123). A given dose of a drug will 
not give the same blood concentration in all individuals, and the same blood 
concentration will not lead to the same level of symptoms for all individuals. Also, 
the same concentrations may give different symptoms at increasing or decreasing 
blood drug concentration curve. All these factors will contribute to obscuring a 
dose-response relationship. 
Assessment of diagnoses and symptoms 
Diagnoses were taken from the records, and for those who had been interviewed 
with Mini-International Neuropsychiatric Interview (MINI) and the 7-item Iowa 
Personality Disorder Screen, these interviews were taken into account when the 
diagnoses were given at discharge. All clinical diagnoses were routinely confirmed 
by a ward psychiatrist. However, for 37% of the admissions at Lovisenberg and all 
the admissions from Arendal, structured interviews were not performed. Clinical 
diagnoses are not always reliable (132), and even when MINI-interviews have 
been performed, the test-retest reliability was only moderately good (133). One 
can speculate if this led to an underestimation of how many patients were 
diagnosed with a primary psychotic disorder. As the wards were crowded, it may 
have been easier to discharge patients after a few days if they were assessed as 
having a drug-induced psychosis.  
The positive subscale of the Positive and Negative Syndrome Scale (PANSS) was 
uses to assess positive psychotic symptoms. This instrument was developed to 
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assess psychotic symptoms in patients with schizophrenia (113). As far as we 
know, no data have been published on its reliability and validity in acute 
psychiatric settings, but it has been used on acute psychiatric wards among 
patients with bipolar disorders and schizophrenia without any report of serious 
validity problems (134). 
Global assessment of functioning and symptoms (GAF, split version) was routinely 
stated at admission and at discharge. The reliability is low when assessing 
individual patients with GAF (135). 
 
6.3 External validity 
I have now discussed internal validity, which is a premise for external validity (126). To 
which populations can our results be generalized?  
We compared our results to data from a national report from 2006 which used data 
from 19 acute psychiatric wards in Norway (N=3572) collected in 2004/2005, i.e. 
about the same time period as our study. We found no differences with regard to age, 
gender, GAF scores, length of stay and disorders not related to substance disorders. 
However, the patients from Lovisenberg differed in some respects from patients both 
at Arendal and in the national survey. They were more often of non-Norwegian origin 
(20% vs 0% in Arendal and 10% nationally), were more often homeless (10% vs 4% 
and 4%) and more often had a substance use disorder as their discharge diagnoses 
(45% vs 36% and 22%) (no p-values because we only have aggregated data from the 
national survey).  
Since Oslo is the largest city in Norway and also the capital, the composition of the 
population is different. The proportion of immigrants is higher in Oslo, and it has been 
reported that non-western immigrants have lower drug use levels than the rest of the 
population, both in the population in general (136) and among acutely admitted 
patients (137). On the other hand, substance use is more common in Oslo than in 
rural areas (138). 
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All in all, our results are probably representative for patients admitted to the two 
hospitals included in the study, but are probably not representative for the entire 
country or for other countries (139). 
With regard to DUI cases, we got very similar results when we analysed all cases for 
the entire country compared to the cases from the same geographical area as the two 
hospitals. The DUI cases were chosen because they involved analysis of a large group 
at the same laboratory, with the same analytical repertoire and in the same time 
period. However, we do not know the extent to which the DUI cases are 
representative for all users of amphetamines in Norway or if the DUI cases were a 
suitable comparison group to psychiatric patients. The conclusion that 
methamphetamine is more likely to cause psychosis than amphetamine is based on 
the assumption that individuals who have been arrested will have fewer or less severe 
psychotic symptoms than those who are admitted to acute psychiatric wards. We 
cannot totally exclude the possibility that any of the apprehended drivers were 
psychotic, but the drivers had been subject to a short clinical examination, increasing 
the chance that they were not psychotic. Neither can we exclude the possibility that 
some of the drivers were later taken to psychiatric wards after apprehension and 
would, therefore, have been counted in both groups. However, since the number of 
DUI cases (n = 988) was so much larger than the number of patients (n=51), this 
would, at worst, have affected a very small number of cases. 
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7. Results 
Overview of material 
The number of patients is summarized in table 1. In the pilot study from 2003 which 
had 87 acutely admitted patients with a total of 100 admissions, 63% (95% CI 54%-
73%) of the admissions and 61% (51%-71%) of individual patients had psychoactive 
drugs in their blood or urine or both. We did not register if any of them were given 
psychoactive drugs after admission and before sampling of blood and urine tests. 
From the main study in 2006/2007, 64% (59%-69%) of the 331 admissions and 63% 
(58%-69%) of the 285 individual patients had psychoactive drugs in their blood or 
urine or both when we corrected for those who had received psychoactive drugs 
between admission and blood sampling. Fifteen different substances were found in 
blood and/or urine: amphetamine, methamphetamine benzodiazepines (alprazolam, 
clonazepam, diazepam, flunitrazepam, nitrazepam), zopiclone, methadone, codeine, 
morphine, 6-MAM (from heroin), cocaine, THC (from cannabis) and ethanol.  
 
Specific aims 
Aim 1: How many patients acutely admitted to a psychiatric ward were positive for 
amphetamine/methamphetamine (paper I and III)?  
In the pilot study from 2003, we found that of 87 individual patients, 17 (20%, 95% CI 
11%-28%) were positives for amphetamines in blood and/or urine. Among the 285 
patients included in the main study from 2006/2007, 38 (13%, 95% CI 9%-17%) were 
amphetamine positive in blood and/or urine, and 35 (92%, 95% CI 84%-101%) of these 
were also positive for methamphetamine in blood and/or urine.  
 
Aim 2: Which other psychoactive drugs did the amphetamine positives have in their 
blood/urine (paper I and III)? 
Of the 17 patients who were positives for amphetamines in the pilot, 13 (76%, 95% CI 
56%-97%) had at least one psychoactive drug in their blood/urine in addition to 
amphetamine and methamphetamine. The 17 patients had a median of 1 (SD 0.862, 
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range 1-3) of psychoactive drugs including amphetamines in blood/urine at 
admission. Of the 38 patients who were positives for amphetamines in the main 
study, 33 (87%, 95% CI 76%-98%) were also positives for psychoactive drugs including 
amphetamines with a median of 4 (SD 2.2, range 1-10) of psychoactive substances in 
blood/urine at admission. The following drugs were found in addition to 
amphetamines: benzodiazepines (alprazolam, clonazepam, diazepam, flunitrazepam, 
nitrazepam), zopiclone, methadone, codeine, morphine, 6-MAM (from heroin), 
cocaine, THC (from cannabis) and ethanol.  
With regard to the 735 apprehended drivers in our study, we only had blood samples, 
not urine samples, and all of them were positive for amphetamines. Of these, 623 
(84%, 95% CI 82%-87%) had at least one other psychoactive drug in their blood with a 
median of 3 (SD 1.151, range 1-10) drugs including amphetamines. Of the patients 38 
patients who were positive for amphetamines in their blood, 28 (74, 95% CI 60%-88%) 
had at least one other psychoactive drug in their blood with a median of 2 (SD 1.599, 
range 1-7) including amphetamines. Among the apprehended drivers, we found the 
same drugs as among the patients, in addition to ecstasy, carisoprodol/meprobamate, 
ethylmorphine, oxazepam and zolpidem. 
 
Aim 3: Which socio demographic characteristics do the amphetamine-positive 
patients have (paper I)? 
Compared to those who were negatives for amphetamines, we found that those who 
were positives for amphetamines were more often male, 71% (95% CI 57%-85%) vs. 
45% (95% CI 38%-51%), more often had fewer than 9 years of education, 71% (95% CI 
57%-85%) vs. 49% (95% CI 42%-55%), more often lived alone, 87% (95% CI 76%-98%) 
vs. 64% (95% CI 58%-70%) or were homeless, 26% (95% CI 12%-40%) vs. 6% (95% CI 
3%-9%) and were more often involuntarily admitted, 63% (95% CI 48%-78%) vs. 47% 
(41%-53%). None of the amphetamine/methamphetamine positives cared for 
children, 0 % vs. 13 % (95% CI 8%-17%). During their stay, these patients were also 
more often subjected to coercive measures than amphetamine/methamphetamine 
negative patients, 34% (95% CI 19%-49) vs. 17% (95% CI 12%-22%). 
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Aim 4: What are the symptoms of psychosis induced by amphetamines compared to 
schizophrenia in the acute phase (paper I and IV)?  
We compared PANSS scores at the positive subscale for those 1) patients who 
received a diagnosis of schizophrenia and were negatives for amphetamines in blood 
and/or urine with PANSS scores to 2) patients who were positive for amphetamines in 
blood and/or urine and either received a diagnosis of amphetamine-induced 
psychosis or psychoses induced by multiple drugs. Nine patients were in the group 
with amphetamine/drug-induced psychoses, and from these 8 individual patients had 
PANSS scores for all seven items at the positive subscale. 33 individuals were 
diagnosed with schizophrenia, and from these 31 had PANSS scores for all seven 
items. We found no differences in PANSS scores between the two groups (paper I). 
We also did an ANOVA to compare the PANSS scores between the same two groups 
and got very similar results; those positive for amphetamines with drug-induced 
psychoses had a total PANSS-score of 22.8 and the negatives with schizophrenia 23.5 
(p = 0.783). For each sub-scale of PANSS, we also got very similar results when we did 
ANOVA, which showed the same trends as Student’s T-test. We also carried out a 
post-hoc analysis where we excluded all patients who were positive for any sedating 
drug, i.e. benzodiazepines, THC, ethanol and/or opiates/opioids. The patients with 
schizophrenia, who were negative for all drugs (N = 17) had a mean PANSS score of 
24.8. Only two patients with drug/amphetamine-induced psychosis were positive for 
amphetamines and no sedating drugs, and only one of these had a total PANSS score, 
positive subscale. This one person had a score of 28.0 (p = 0.671). We found similar 
non-significant results for all the subscales of PANSS. 
When we corrected for being positive for sedating drugs, both for individual drugs 
and taken together, we found a tendency towards slightly higher PANSS scores among 
those with amphetamine or drug-induced psychoses (table 5). 
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Aim 5: Is there a relationship between blood concentrations of amphetamines and 
psychotic symptoms (paper I)? 
With rising blood levels of amphetamine/methamphetamine only very marginal 
differences in symptoms, as measured by PANNS, were observed. We found that 
individuals who were positives for amphetamines in urine only (N=9) had a PANSS 
score at 18.0 (95% CI 8.9-27.1). Those who were positives in blood with low/moderate 
concentrations of amphetamines (ч270 ng/ml) (N=15) had a PANSS score of 20.6 (95% 
CI 15.5-25.7) and those with high concentrations of amphetamines (271-1052 ng/ml) 
(N=8) had a PANSS score of 20.9 (95% CI 14.1-27.7), p=0.782. For the seven individual 
items of PANSS, similar tendencies were found (table 6). 
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Aim 6: What is the relationship between having positive blood samples for 
amphetamines use of amphetamines and physician’s assessment of drug influence? 
(paper II) 
Of the 271 admissions included, 27 (10%) had positive blood samples for 
amphetamines. All of these were assessed by the physician on call as being under the 
influence of amphetamines. Three admissions with no drugs detected in their blood 
samples were judged by the physician as being under the influence of amphetamines. 
For these patients, recent use of amphetamines was reported. When adjusted for age, 
gender, psychotic symptoms and blood drug concentration scores, having 
amphetamines in the blood were associated with an increased likelihood of being 
judged clinically to be under the influence of drugs (OR 5, 95% CI 1-17) compared to 
other substances in the blood.  
 
Aim 7: Is methamphetamine more prevalent than amphetamine among acutely 
admitted patients compared to apprehended drivers (paper III)? 
We studied the proportion of methamphetamine positives among all patients and 
DUI cases with positive blood samples of amphetamines. In 2003, 5 (45 %) of the 
psychiatric patients (N=11) were positive for methamphetamine. In the same year, 
85 (29 %) of the DUI cases who were from the same area (N=294), were positives 
for methamphetamine. In 2006/2007, 23 (85 %) of the psychiatric patients (N=27) 
were methamphetamine positives. Among the DUI-cases in the same area and 
time period, 257 (58 %) were methamphetamine positives (N=441). Taken 
together across the two time periods 28 (74%) of the psychiatric patients (N=38) 
were positive for methamphetamine and 342 (47%) of Norwegian DUI cases from 
the same area (N=735).  
We did a binary logistic regression where we compared the odds for being 
admitted to an acute psychiatric ward compared to being apprehended in traffic. 
When we adjusted for gender, age, being methamphetamine positive, 
concentration of the sum of amphetamine and methamphetamine and influence 
of sedating drugs, we found that individuals who had taken methamphetamine 
had a 3-4 times increased risk of being admitted to an acute psychiatric ward 
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compared to those who had taken only amphetamine (adjusted OR= 4.423 (2.031 
– 9.631)). 
 
Aim 8: Are there any differences in concentrations between amphetamine and 
metamphetamine among psychiatric patients compared to DUI cases? (paper III) 
The mean methamphetamine concentration was 1.3ng/ml (SD 1.7) among psychiatric 
patients and 1.3 ng/ml (SD 2.8) among DUI cases (Student’s T-test, p-value = 0.961). 
The patients with psychiatric diagnoses, compared to the DUI cases, had lower mean 
concentrations of amphetamine (0.9 ng/ml vs. 2.6 ng/ml; p < 0.001, Student’s T-test) 
and hence a lower total concentration of amphetamines together (2.2 ng/ml vs. 3.9 
ng/ml, P < 0.001, Student’s T-test). Fewer patients with psychiatric diagnoses were 
positive for sedatives and hypnotics than among the DUI cases, 18 (47 %) vs. 520 (717 
%) (p < 0.01, ʖ2-test).  
 
Aim 9: How many of those diagnosed with amphetamine/methamphetamine-
induced psychosis later received a diagnosis of schizophrenia? (paper IV) 
Of the 35 amphetamine positives included from the original study, seven had a 
diagnosis from the chapter schizophrenia, schizotypal and delusional disorders (F20-
F29 according to the ICD-10 classification of mental and behavioural disorders). 10 
moved out of the hospital’s catchment area. Six were dead. This left us with 12 
individual patients who received diagnoses specifically related to disorders due to 
psychoactive substance use (F10-F19 according to the ICD-10 classification of mental 
and behavioral disorders). From these 12 patients, two received the diagnosis F19.5 
Psychotic disorder, amphetamine-induced and two the diagnosis F19.7 Multiple and 
late-onset psychotic disorder, amphetamine-induced. One got the diagnoses F90.0 
Hyperkinetic disorder, disturbance of activity and attention and F60.31 Emotionally 
unstable personality disorder, borderline type. The remaining seven got drug-related 
diagnoses when first included in the study in 2006/2007.  
When we scored the original admission records, we also found that three patients had 
visual hallucinations. Two received a diagnosis of Schizoaffective disorder (F25.1 and 
F25.2, respectively), and the last one a diagnosis of F60.3 Emotionally unstable 
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personality disorder. One saw colours, the two others “saw people” and did not 
change diagnosis before moving out of the catchment area later in 2007. 
When we did the follow-up in 2012, four patients had been re-diagnosed with 
schizophrenia, three of these with F20.0 Paranoid schizophrenia and one with F20.3 
Undifferentiated schizophrenia. 
 
Aim 10: What characterises those who experience this transition? (paper IV) 
With regard to baseline characteristics, we found small differences between those 
who had been re-diagnosed with schizophrenia (change group) and those who had 
not. The change group had less dramatic symptoms on admission measured by PANSS 
compared to the stable group, 16.7 vs 22.5 points (student’s T-test, p = 0.580). For the 
different sub-scores of PANSS, the largest difference between the two groups was in 
hallucinatory behaviour, 3.3 vs 1.0 points (student’s T-test, p = 0.023). As scored by 
SAPS-CIP, one person in the stable group had auditory hallucinations (”People talking 
to subject”), two had persecutory delusions (“Someone is going to harm the subject”), 
and one had somatic persecutions (felt body was “changed”). In the change group, 
one person had had persecutory delusions (“Someone is going to harm the subject”). 
The stable group had more pronounced baseline symptoms with regard to 
suspiciousness, hostility and hallucinatory behaviour measured by PANSS, the 
difference regarding hallucinations being the only significant result (p=0.023). 
The change group had a lower level of function at admission and even more at 
discharge, as measured by GAF, and the improvement in function was less for the 
change group than for the stable group, 5 vs 12 points (student’s T-test, p=0.165). 
The concentration of amphetamine and methamphetamine taken together was higher 
among the change group than in the stable group, 1.7 mmol/L vs 0.9 mmol/L 
(student’s T-test, p=0.663). The total number of drugs detected were slightly lower in 
the change group, 4.0 vs 4.9 (p=468). Sedating drug influence among those who were 
positives for any sedating drug, was also slightly lower in the change group, 1.6 points 
vs 1.3 points (p=0.370). 
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8. Discussion 
The results will first be discussed in line with the aims. Then the objectives at a higher 
level will be discussed. 
 
1. Admissions related to amphetamines took up a large proportion of the beds in 
acute psychiatric wards. 
We found that 20% of individuals (95% CI 11%-28%) in the pilot study from 2003 and 
13% (95% CI 9%-17%) in the main study from 2006/2007were positives for 
amphetamines in blood and/or urine. This indicates a fairly stable pattern of 
amphetamine use. In the pilot study, blood samples were also collected among 
medical admissons at Lovisenberg Diakonale Hospital. From these (N=106), 3 (3%) 
were positives for amphetamines (108). Thus, patients admitted to an acute 
psychiatric ward were much more likely to have amphetamines in their blood and/or 
urine than a comparison group from the same time period and catchment area. This 
higher use of amphetamines among psychiatric inpatients is in line with other studies 
from Norway (140;141) and elsewhere (19;20;20;28;142;143). 
 
2. The majority of amphetamine positives acutely admitted to psychiatric wards had 
high rates of recent intake of other psychoactive substances. 
In the pilot, 76% (95% CI 56%-97%) had at least one psychoactive drug in their 
blood/urine in addition to amphetamine and methamphetamine with a median of 1 
(SD 0.862, range 1-3) psychoactive drug including amphetamines in blood/urine at 
admission. In the main study, 87% (95% CI 76%-98%) of the amphetamine positives 
were also positive for psychoactive drugs including amphetamines with a median of 4 
(SD 2.2, range 1-10) psychoactive substances in blood/urine at admission (paper I). 
Again, the results from the pilot were replicated three years later and show a stable 
pattern of drug use. Other studies have also found frequent poly drug use among 
users of amphetamines (144;145). In our study, the substances which were found in 
addition to amphetamines were all sedating.  
It can be debated whether the pattern found on admission to acute psychiatric wards 
is representative of poly drug use among amphetamine users. Amphetamines are 
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often taken in “runs” where users stay awake for several days (19;27;27;146-148). 
These “runs” often end with the intake of sedating drugs like THC, ethanol, opioids or 
benzodiazepines. Those individuals included in our study may have been admitted 
after trying, unsuccessfully, to self-medicate with sedating drugs. It is not, therefore, 
unlikely that we might find a higher percentage of poly drug use in our study 
compared to users of amphetamines in other settings. 
 
3. Amphetamine users who were admitted to acute psychiatric wards were socially 
marginalized compared to other patients acutely admitted to psychiatric wards.  
We found that those who used amphetamines and were admitted to acute psychiatric 
wards, compared to other patients admitted to the same wards in the same time period, 
were younger and more often male, more often had fewer than 9 years of education, more 
often lived alone and were homeless. This is in line with other studies (52;75;149). 
 
4. Patients who had taken amphetamines and had a diagnosis of psychotic disorder 
induced by methamphetamine or multiple substances did not show different symptoms 
from patients with schizophrenia who had not taken amphetamines.  
We found the positive psychotic symptoms of the two groups, as measured by PANSS, to be 
very similar. Despite difficulties in comparing different studies which use different symptom 
measures, this confirms earlier studies which have reported problems in distinguishing 
methamphetamine-induced psychosis from primary psychoses, be it in experimental studies 
where amphetamine was given (45;47) or later observational studies of methamphetamine 
users (56;57;71). 
A limitation was that we did not register symptoms of visual hallucinations and were, 
therefore, not able to compare with studies which found that visual hallucinations 
characterized amphetamine-induced psychosis as opposed to schizophrenia (44;54). It is also 
possible that the more vivid symptoms of amphetamine/methamphetamine-positive 
patients were masked by the concomitant use of sedating drugs. Almost all the patients 
were poly drug users, which may be a confounding factor. 
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5. We found no clinically or statistically significant relationship between blood 
amphetamine/methamphetamine levels and symptoms.  
A cardinal sign of causality in pharmacology is a concentration-effect relationship. We found 
no statistically significant relationship between blood amphetamine/methamphetamine 
concentrations and the intensity of positive psychotic symptoms, and this is in agreement 
with two earlier studies (48;150).  
This lack of a relationship between symptoms and blood concentration may be because the 
development of psychosis is related more to vulnerability than to methamphetamine 
exposure. We know that methamphetamine users are more likely to develop psychosis if 
they have first degree relatives with schizophrenia (151) or pre-morbid schizoid/schizotypal 
personality. There is also evidence to suggest shared genetic components between 
methamphetamine induced psychosis and schizophrenia and to suggest (152) that 
individuals with some genetic variants of the dopamine receptor, subtype 2 (DRD2) are more 
likely to have rapid onset, prolonged duration and spontaneous relapse of 
methamphetamine psychosis (153;154). Another possible explanation is sensitization to the 
effects of methamphetamine (155-157). A chronic course of methamphetamine psychoses is 
associated with frequent use (52) and early onset of methamphetamine use (52;75). A third 
explanation may be related to the fact that almost all the patients were poly drug users 
which has probably obscured the relationship between blood concentrations and symptoms. 
Those individuals included in our study may be admitted after trying, unsuccessfully, to self-
medicate. Lastly, some of the patients may have been hospitalized during a withdrawal 
phase for methamphetamine rather an intoxication phase (129;130;131). Some may also 
have been in the intoxication or withdrawal phase of drugs other than methamphetamine. 
 
6. When adjusted for age, gender, psychotic symptoms and blood drug concentration 
scores, amphetamines were associated with an increased likelihood of being clinically 
judged to be under the influence of drugs. 
Patients who were positives for amphetamines had an increased chance of being judged by 
the physician as influenced by drugs. The association was, however, only moderately strong. 
A study where blood values of amphetamine and clinical assessment among acutely 
poisoned patients were compared also showed moderate agreement (158). The lack of a 
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strong relationship between blood concentrations of amphetamines and the chance of being 
judged as influenced, is probably due to many of the same factors as described above, under 
aim 5, about why there is no relationship between blood levels of amphetamines and 
symptoms, i.e. individual differences in personal vulnerability, possible sensitization to the 
effects of amphetamines (155-157) and poly drug use (19;27) and the fact that some may 
have been in a withdrawal phase rather than in an intoxication phase for amphetamines 
(129-131) or other drugs or both. Three patients were judged as being influenced by 
amphetamines when they had negative blood and urine samples. This may indicate that 
some regular substance users were misinterpreted as being under the influence at the time 
of admission, or that symptoms of withdrawal were perceived as being influenced by drugs. 
Also, because of sampling delay and the fact that amphetamines may have been taken 
several days before admission, clinicians may have seen influence that was confirmed by 
history taking, but not by analyses. 
 
7. Methamphetamine was more prevalent than amphetamine among acutely admitted 
patients compared to apprehended drivers. 
The observed increase in the share of methamphetamine in both groups over time is in line 
with seizure statistics from the National Crime Investigation Service (76), which shows a 
steady increase in the availability of methamphetamine in Norway between 2000 and 2010. 
However, the patients with psychiatric diagnoses were more often methamphetamine-
positive than apprehended drivers both in 2003 and in 2006/2007. Since most users will not 
be aware of which they are taking (80), the difference between the groups was probably not 
due to preference. Our findings could, therefore, point to methamphetamine being a more 
potent drug in producing psychiatric symptoms like psychosis. The finding that 
methamphetamine was more prevalent among the patients admitted to acute psychiatric 
wards, and the lack of a concentration-effect relationship may support earlier findings that 
methamphetamine has a mode of action which is qualitatively different from that of 
amphetamine (102-104). 
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8. The blood drug concentrations both for amphetamine alone and for the total 
concentrations of amphetamines (i.e. amphetamine and methamphetamine) were lower 
among those who were admitted to acute psychiatric wards than in DUI cases. 
A concentration-effect relationship would have strengthened a hypothesis of causality 
between the use of amphetamines and psychiatric and psychotic symptoms. We found, 
however, that the concentrations of both amphetamine alone and the total concentration of 
amphetamine plus methamphetamine were lower among patients with psychiatric 
diagnoses than in the control group. This could suggest that the psychiatric symptoms and 
psychosis were caused not only by the use of the drugs, but that some individuals are more 
vulnerable to psychiatric and psychotic symptoms (159). However, a concentration-effect 
relationship may have been obscured by other factors commonly associated with the use of 
amphetamines. We may have measured the concentration of amphetamines among the 
patients in the withdrawal phase for amphetamine rather than in an intoxication phase 
(129). Like previously mentioned, amphetamines are often taken in “runs” (19;27;146-148) 
where users at the end of a run, self-medicate by sedating drugs. The apprehended drivers 
were, in fact, more influenced by sedating drugs than the psychiatric patients. This may 
reflect a greater degree of “success” among apprehended drivers in treating their 
amphetamine induced “high” than those who are acutely admitted to a psychiatric ward. 
With our current results, it is difficult to conclude whether the psychiatric problems were 
due to the intake of amphetamines, or due to personal vulnerability. It is likely, though, that 
there is a continuum of personal vulnerability between the two groups with hospitalization 
in a psychiatric ward as a more likely outcome for the most vulnerable. 
 
9. One third of those diagnosed with amphetamine/methamphetamine-induced psychosis 
have received a diagnosis of schizophrenia five years later. (paper IV) 
This is in line with the few other studies in the field, which have also found that some 
patients who are diagnosed with substance-induced psychosis (74) or methamphetamine 
psychosis (75) are later diagnosed with schizophrenia. There were few differences with 
regard to baseline characteristics between those who changed diagnosis and those who did 
not. 
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10. What characterises those who experience this transition? (paper IV) 
Even though the differences were small and not statistically significant, we are able to 
see some tendencies. The change group had a lower level of function compared to the 
stable group as measured by PANSS and the level of function improved to a lesser 
extent during the stay. All but one were homeless as opposed to none in the stable 
group, and all of the individuals in the change group had previous psychiatric 
admissions. These results may suggest that, at the time of our study, they were 
showing negative symptoms of schizophrenia. Our finding that three of the 
amphetamine-positive patients had visual hallucinations is in line with earlier studies 
(52-54). 
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Objectives 
Our first objective was to investigate whether there were clinically evident differences 
between psychosis induced by amphetamines and acute symptoms of schizophrenia. 
According to our results, there are few differences in the acute phase, i.e. at the time 
of admission to acute psychiatric wards (paper 1). This is in line with some other 
studies (42;43;56;57) which found it hard to distinguish between the two groups. 
However, others have found visual hallucinations to be more common in psychosis 
induced by amphetamines (44;45;52-54). It was one of the limitations of our original 
study that we did not examine visual hallucinations. When we did the follow-up and 
scored the original admission records of patients positive for amphetamines we found 
that three patients had visual hallucinations. Visual hallucinations were not common, 
however, and we still think it is very difficult to distinguish between psychosis induced 
by amphetamines and schizophrenia in the acute phase. It is possible that there is a 
dose-response relationship between use of amphetamines and visual hallucinations, 
i.e. that most individuals will develop other symptoms like delusions, hostility and 
suspiciousness first, and visual hallucinations later as a high-dose response (144). 
What constitutes a high dose will, however, vary between individuals. 
Our next objective was to investigate if methamphetamine was more potent in 
generating psychosis than amphetamine. We found that individuals who had taken 
methamphetamine had a 3-4 times increased risk of being admitted to an acute 
psychiatric ward as opposed to be apprehended by the police compared to those who 
had taken only amphetamine. We also found that the mean methamphetamine 
concentration was the same in the two groups, but the concentrations of 
amphetamine alone and hence the total concentration of amphetamine plus 
methamphetamine, were lower among patients with psychiatric diagnoses than 
among the DUI-cases. This could suggest that the psychiatric symptoms and psychosis 
were caused not only by the use of the drugs, but that some individuals are more 
vulnerable to psychiatric and psychotic symptoms (paper III). We found no 
relationship between symptoms and blood concentrations of amphetamines within 
the patient group (paper I) and no strong relationship between being positive for 
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amphetamines and being judged as under the influence of drugs by the physician on 
call (paper II). 
Finally, we wanted to investigate whether there is a transition from psychosis induced 
by amphetamines to schizophrenia and found that one third of the patients admitted 
to an acute psychiatric ward with amphetamines in blood/urine and who did not get a 
diagnosis of primary psychosis at that time, were diagnosed with schizophrenia during 
the five year follow-up. This was a case series and hence, our results were not 
statistically significant (paper IV).  
On the basis of our main findings, we propose a model for understanding the 
relationship between schizophrenia and psychoses induced by amphetamines. It is 
known that having first degree relatives with schizophrenia (151) or pre-morbid 
schizoid/schizotypal personality (52) increase the risk of developing psychosis when 
exposed for amphetamines. ADHD (160) and other neurological disorders during 
childhood (161) may also play a role. A chronic course of methamphetamine 
psychoses is associated with frequent use (22;52;162) and early onset of 
methamphetamine use (52;75;163;164) as well as injection as the preferred route of 
administration (144). Those who inject may have more high-dose related symptoms 
because injection of amphetamines is connected to higher doses (59;165). Individual 
differences in vulnerability to developing psychoses explains why some individuals 
seem not to develop psychotic symptoms at all when using amphetamines 
(42;45;48;51), others develop symptoms when exposed for larger doses and some for 
smaller doses (41;47). We believe that the relationship between psychosis induced by 
amphetamines and schizophrenia can be understood within a traditional stress-
vulnerable model (151;159;166;167). The endpoint here is schizophrenia, which the 
individuals most vulnerable to psychoses develop without any exposure to 
amphetamines or other stimulants. A stress–vulnerability model may also explain why 
some individuals develop a more chronic psychotic condition when exposed for 
amphetamines (31;44;52;62;168). 
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Clinical implications and final word 
My time as a PhD student is now over and I am back to clinical practice. Diagnostic 
entities now seem more uncertain to me than ever. When patients are acutely 
admitted, it is not possible to assess from the symptoms whether they have a primary 
psychotic disorder like schizophrenia or a drug-induced psychosis alone or a 
combination of the two. The physician’s assessment of whether the patient is under 
the influence of drugs like amphetamines is burdened with uncertainty. I have learned 
that a diagnosis is not final, but may change over time – either because the patient is 
misdiagnosed with drug-induced psychosis in the first place or because patients who 
initially have a drug-induced psychosis may develop schizophrenia over time. It 
saddens me to see how difficult the living conditions are for patients positive for 
amphetamines and how poor their prospects are in many respects. A few years on, 
some of our patients initially diagnosed with amphetamine-induced psychosis have 
been re-diagnosed with schizophrenia and several of the amphetamine positives are 
dead (paper IV). 
An important clinical implication of our results is that patients with dual diagnosis may 
be mis-diagnosed as only having a drug-induced psychosis. They may not receive the 
correct treatment or get social benefits they otherwise would have been entitled to. 
This should have consequences for how services for dual-diagnosis patients are 
organized, whether specialist teams for dual-diagnosis are established (32), or health 
care workers in the existing systems receive better training (33).
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 Informasjon og samtykke
Forespørsel om deltakelse i forskning
Lovisenberg Diakonale Sykehus 
Nasjonalt Folkehelseinstitutt  
 
 
Vil du delta i forskningsprosjektet 
 
”Rus i akuttpsykiatrien”? 
 
 
Kjære nyinnlagte pasient! 
Mange psykiatriske pasienter bruker eller har brukt rusmidler. 
Sammenhengen mellom rus og psykisk helse er et viktig og komplisert 
felt hvor det ønskes mer kunnskap. Derfor spør vi om du vil bli med i et 
forskningsprosjekt hvor vi skal undersøke dette nærmere. Vi ønsker å 
kartlegge psykisk helse og rusvaner hos alle nyinnlagte pasienter ved 
akuttpsykiatrisk avdeling. Det er viktig at både pasienter som bruker og 
ikke bruker rusmidler deltar. Ved din deltakelse vil du gi et verdifullt 
bidrag til et forskningsprosjekt som ønsker å bidra til bedre utredning og 
behandling i akuttpsykiatrien.  
    
Studieinnhold 
1) Vi ber om tillatelse til å hente opplysninger fra din journal til bruk i 
forskningsprosjektet. 
2) Vi ber om tillatelse til å intervjue deg om din psykiske helse og dine 
rusvaner. Intervjuene varer cirka en time og gjøres i løpet av 
oppholdet her.   
3) Ved innleggelsen ble det rutinemessig tatt blodprøve og urinprøve. 
Vi ber om tillatelse til å analysere prøvene med hensyn til 
rusmidler.  
 
Datasikkerhet 
1) Medarbeiderne i prosjektet har taushetsplikt, og all informasjon om 
deg vil bli behandlet konfidensielt. Personlige opplysninger vil kun 
brukes til forskning og vil ikke kunne kobles til deg.  
2) Blodprøvene og urinprøvene analyseres og oppbevares ved 
Nasjonalt Folkehelseinstitutt. Der opprettes det en egen biobank 
for dette prosjektet, som divisjonsdirektøren er ansvarlig for. 
Prøvene er ikke tilgjengelig for noen andre. Analysene tar noe tid, 
og svarene vil kun brukes til forskning. Prøvesvarene blir derfor 
ikke tilgjengelig for deg, din behandler eller din journal.     
3) Intervjuene med deg vil også gi viktig informasjon. Du har rett til å 
få innsyn i disse opplysningene og til å få noe endret hvis det er 
feil. Denne informasjonen legges i journalen din, og kan være 
nyttig for din behandling.  
 Informasjon og samtykke
Forespørsel om deltakelse i forskning
Lovisenberg Diakonale Sykehus 
Nasjonalt Folkehelseinstitutt  
 
 
 Rekvirere blodprøver så snart som mulig (ø-hjelp, ”prosjekt”). Obs! Trengs suppl. undersøkelser? 
Du skal ikke informere om prosjektet i innkomstsituasjonen. Dette gjøres senere. Legg ferdig utfylt 
skjema i medisinkardex for aktuelle pasient, og kryss av i ”sjekkliste”. TAKK FOR SAMARBEIDET! 
Innkomst-skjema ”Rus i akuttpsykiatrien 2006”Lovisenberg Diakonale Sykehus Nasjonalt folkehelseinstitutt   
 
Spørsmål til mottagende lege: 
Skal besvares for alle nyinnlagte pasienter 
(Se viktig informasjon helt nederst) 
 
 
 
 
 
 
          
 
 
 
På bakgrunn av alle tilgjengelige data ved innkomstvurdering 
 
1) I løpet av den siste uken og ved innkomstvurdering: I hvilken 
grad har pasienten hatt positive symptomer?  
(Markér høyeste score i denne perioden, se PANSS –veil. på baksiden) 
 
Vrangforestillinger              1     2     3     4     5     6     7 
Tankemessig desorganisering     1     2     3     4     5     6     7 
Hallusinasjoner    1     2     3     4     5     6     7 
Uro / agitasjon    1     2     3     4     5     6     7 
Storhetsidéer    1     2     3     4     5     6     7 
Mistenksomhet / forfølgelsesidéer 1     2     3     4     5     6     7 
Fiendtlighet     1     2     3     4     5     6     7 
 
2) Opplysninger om aktuelt inntak av rusmidler (kryss av) 
Ƒ Alkohol      ƑAmfetamin  ƑOrganisk løsemiddel 
Ƒ Benzodiazepiner  ƑKokain      ƑAnnet rusmiddel:____ 
Ƒ Cannabis   ƑMorfin / heroin  Ƒ Ingen opplysninger 
Hvis opplysninger om dette:  
Stoff, mengde, tidspunkt, inntaksmåte: __________________________________ 
 
3) I hvilken grad opplever du at pasienten er påvirket av 
rusmidler ved innkomst? (kryss av) 
Ƒ Ikke påvirket            ƑModerat påvirket   
Ƒ Lett påvirket   Ƒ Tydelig påvirket    Ƒ Ikke mulig å bedømme 
  
4) Hvordan vurderer du rusmidlers betydning for innleggelsen?   
Ƒ Ingen betydning            ƑStor betydning   
Ƒ Moderat betydning Ƒ Ikke mulig å bedømme
  
Dato og tidspunkt:   ____________________            
Signatur, mottakende lege: __________________               
Plasser pasientetikett her 
 
Eventuelt skriv med blokkbokstaver: 
 
Pas. navn:  ______________ 
F. nummer: _______________ 
 
Dato og tidspunkt for 
innkomstundersøkelse 
 
_____________ 
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